Contineum Therapeutics, Inc. CTNM
9.04 USD -0.20 (-2.16%)
Regular-session close
9.04 0.00 0.00%
After hours · Nov 19, 4:26 PM ET
8.93 Day range 9.63
6.73 52-week range 17.79
- YTD
- -20.91%
- 1 year
- -27.27%
News
businesswire.com Qureight's Fibrosis Imaging Biomarker Selected by Contineum Therapeutics as a Secondary Endpoint in Phase 2 PROPEL-IPF Clinical Trial CAMBRIDGE, England & SAN DIEGO--(BUSINESS WIRE)--Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and…benzinga.com Contineum Therapeutics Q3 EPS $(0.49) Misses $(0.45) Estimate Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.45) by 8.89 percent. This is a 8.89 percent decrease over losses…
businesswire.com Contineum Therapeutics Reports Third-Quarter 2026 Financial Results SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for…
zacks.com All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
benzinga.com Why Is Contineum Therapeutics Stock Falling Monday? Contineum Therapeutics Inc. (NASDAQ:CTNM) stock plunged Monday following mixed Phase 3 trial results for Bristol Myers Squibb & Co.'s (NYSE:BMY) competing lung disease drug, admilparant.
defenseworld.net 48,108 Contineum Therapeutics, Inc. $CTNM Shares Sold by Squarepoint Ops LLC Squarepoint Ops LLC lessened its position in shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM) by 80.4% during the second quarter, according to the company in its most recent 13F filing with the…
defenseworld.net Contineum Therapeutics (NASDAQ:CTNM) Trading Down 9.9% After Analyst Downgrade Shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) dropped 9.9% during mid-day trading on Tuesday after JonesTrading lowered their price target on the stock from $26.00 to…
benzinga.com Johnson & Johnson Partner Contineum Slides as Depression Drug Fails Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint.
businesswire.com Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for…
businesswire.com Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for…
businesswire.com Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for…
zacks.com Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum investors? Let's find out.
gurufocus.com Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the t
businesswire.com Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of…
businesswire.com Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of…
zacks.com Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High? The consensus price target hints at a 60% upside potential for Contineum Therapeutics, Inc. (CTNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend…
marketbeat.com Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential Contineum Therapeutics NASDAQ: CTNM President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent…
businesswire.com Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of…
businesswire.com Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of…
businesswire.com Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of…
zacks.com Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 49.2% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is…
